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Abstract 
 
Background: Human insulin-like growth factor type 1 (hIGF-1) is a protein consisting 
of 70 amino acids (MW=7.6 kDa) and mainly synthesized by liver. Mecasermin (Trade 
name INCRELEX) is the synthetic form of the protein which is used as an effective 
treatment for particular disorders such as short stature, type 1 and 2 diabetes, and 
wound healing. Current study was aimed to investigate the expression of human insu-
lin-like growth factor type1 in Escherichia coli (E. coli) BL21 (DE3) expression system in 
order to produce an active recombinant form of the protein.  
 
Methods: For the purpose of the study, firstly codon optimization was done for hIGF-1 
gene, using bioinformatics databases. Then, the gene was synthesized and inserted in 
pET-24a vector by a cutting strategy included NdeI and BamHI-HF enzymes. In the 
next step, gene was run in agarose gel and purified. The constructed expression cas-
sette was transformed into E. coli BL21 (DE3) cells through CaCl2 heat shock method. 
Identification and confirmation of the transformed colonies were performed using 
screening PCR method. Synthesis of hIGF-1 was induced by IPTG. The expression in in-
duced strains was analyzed by SDS-PAGE and western blotting techniques. Confirma-
tion of cloning and IGF-1 expression cassette was carried out through genetic engi-
neering procedures. 
 
Results: Analysis of transformed E. coli strain with SDS-PAGE and western blotting 
techniques confirmed that gene was expressed in host cells. Molecular weight of the 
expressed protein was estimated to be 7.6 kDa.  
 
Conclusion: hIGF-1 expression cassette for cloning and expression in E. coli was de-
signed and the protein of interest was successfully induced and identified. In addition, 
E. coli BL21 (DE3) can be used as a suitable host for production of recombinant hIGF-1 
and this technology has a potential to be localized. 
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Introduction 
 
Production of recombinant protein provides a suita-
ble method for commercializing medical products 
1
. 
Another advantage of producing recombinant proteins 
is better safety in comparison with sampling of fluids 
from individual 
2
. hIGF-1 has a chemical structure sim-
ilar to proinsulin 
3,4
. IGF-1 is also called  somatomedin 
C, a small 70-amino acid polypeptide with a molecular 
weight of 7649 kDa 
5
. This protein is single chain and 
has three disulfide bonds. IGF-1 is synthesized by  
 
 
 
 
 
many tissues and is secreted from liver as an endocrine 
hormone which is transmitted to other tissues. This 
protein is also secreted by other tissues, including carti-
lage tissue and acts as a paracrine hormone locally 
6
. 
IGF-1 is responsible for cell differentiation, transfor-
mation, suppression of apoptosis, cell cycle progres-
sion, cell proliferation and differentiation. This protein 
stimulates the systemic growth of body and has a 
growth-enhancing effect on every part of the body, 
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especially on skeletal muscle, cartilage, bone, liver, 
kidneys, nerves, skin, hematopoietic cells and lung 
7
. In 
addition to insulin-like effects, IGF-1 can also regulate 
cell growth and development, especially in nerve cells 
via cellular DNA synthesis 
8
. To increase the height of 
children with growth hormone deficiency 
9
 and also to 
treat people who suffer from IGF-1 deficiency such as 
Laron syndrome or Laron-type dwarfism (short stature 
syndrome),  recombinant IGF-1 is prescribed 
8
. The re-
combinant human IGF-1 (Trade name: INCRELEX) 
was approved by FDA of the United States of America 
in 2006 and also received the EP confirmation in 2007 
10
. Due to the high throughput of recombinant DNA 
techniques, the commercial production of peptides and 
proteins in bacterial cells is performed this way 
11
. One 
of the microorganisms which can be used for cloning 
and expression is a special strain of Escherichia coli 
(E. coli). This expression system has many advantages 
such as simple control of gene expression, protein effi-
ciency (up to 50% of total cell protein), having a clon-
ing vector and easy culture 
11,12
. Our main goal was 
cloning and expression of recombinant human insulin- 
like growth factor type 1.  
 
Materials and Methods 
 
Design and synthesis of genes 
Human insulin-like growth factor type 1 is a non-
glycosylated protein and the best expression system for 
this protein is E. coli. Thus, IGF-1 gene was optimized 
for this bacterium. This codon optimization was done 
since IGF-1 is a human protein, while the chosen host 
to produce the recombinant form of protein is E. coli 
which is a prokaryotic cell. In essence, the codon usage 
pattern in E. coli is different from natural host that is 
human. Hence, in order to homogenize the codon usage 
pattern of the desired protein sequence and expression 
in the host and finally overexpression of gene, codon 
optimization and gene synthesis were performed by 
GenScript Corporation. IGF-1 sequence is shown be-
low:  
Then, this gene was sub-cloned into pUC18 plasmid. 
Protein sequence (70 aa) is shown below: 
GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSS
RRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA 
 
Cloning of human insulin-like growth factor type 1 gene in 
E. coli DH5α  
Cloning vector pUC18 and IGF-1 gene were pur-
chased from GenScript (USA). Initially, optimized 
IGF-1 gene was sub-cloned into pUC18. Cloning vec-
tor was transformed into E. coli DH5α competent bac-
teria in order to replicate the plasmid. After the trans-
formation, bacteria were cultured in LB Agar medium 
containing IPTG, X-Gal and ampicillin (50 µg/ml final 
concentration) and were incubated for 16 hr at 37°C. 
Then, using white-blue screening of colonies, trans-
formed bacteria that formed white single colonies were 
picked up by loop and cultured in 100 ml SOC medium 
and incubated in shaker incubator for 12 hr at 37°C. 
Next, bacterial sediment was prepared using centrifuge, 
and replicated plasmids were extracted by plasmid ex-
traction kit (Qiagen, Netherlands). For plasmid confir-
mation, it was run in 1% agarose gel electrophoresis. 
Extracted plasmid concentration was 100 ng/µl. 
 
Enzymatic digestion of pUC18 cloning vector and pET-24a 
expression vector  
Firstly, this plasmid was digested with two restric-
tion enzymes including NdeI and BamHI-HF (BioLabs 
(UK)), for separation of insulin-like growth factor type 
1 gene from pUC18 cloning vector. Then, it was run on 
1% agarose gel electrophoresis and purified with gel 
extraction kit (Qiagen, Netherlands) in order to extract 
the digested gene. Final concentration of obtained gene 
was 14 ng/µl. pET-24a was also digested by these two 
restriction enzymes and prepared for ligation. 
 
Ligation of IGF-1 gene into pET24-a expression vector 
The equation below can be used to calculate the 
quantities of DNA necessary for a particular ratio: 
 
 
 
 
According to BioLab protocol, the best molar ratio is 
3:1. 30 µg of expression vector with 1.27 µg of IGF-1 
gene and 5 µl of T4 DNA Ligase (BioLabs (UK)) were 
used for ligation.  
 
Analysis of transformants by colony screening 
Colonies can be screened for inserts without plasmid 
preparation, by direct colony PCR using vector-specific 
primers. To verify ligation between the vector and in-
sert, a ligation reaction can be analyzed directly by 
PCR using vector-specific primers. For pET-24a, ap-
propriate primers for screening by colony PCR were 
T7 Promoter Primer (TAATACGACTCACTATAGGG) 
and T7 Terminator Primer (GCTAGTTATTGCTCAGC 
GG). According to pET manual from Novagen Compa-
ny, a colony was picked up from an agar plate using a 
sterile toothpick. Colonies chosen were at least 1 mm in 
IGF-1 gene (225 bp) 
Before 
optimization 
CATATGGGTCCGGAAACCCTGTGCGGTGCTGA
ACTGGTTGACGCTCTGCAGTTCGTTTGCGGTGA
CCGTGGTTTCTACTTCAACAAACCGACCGGTTA
CGGTTCTTCTTCTCGTCGTGCTCCGCAGACCGG
TATCGTTGACGAATGCTGCTTCCGTTCTTGCGA
CCTGCGTCGTCTGGAAATGTACTGCGCTCCGCT
GAAACCGGCTAAATCTGCTTGAGGATCC 
After opti-
mization 
CATATGGGCCCGGAAACCCTGTGTGGTGCGGA
ACTGGTGGATGCCCTGCAATTCGTGTGTGGTGA
CCGTGGCTTTTACTTCAACAAACCGACCGGCTA
TGGTAGCTCTAGTCGTCGCGCACCGCAGACCG
GCATTGTGGATGAATGCTGTTTTCGTTCCTGCG
ACCTGCGTCGCCTGGAAATGTACTGTGCGCCGC
TGAAACCGGCGAAAAGCGCCTGAGGATCC 
 
Vector (ng)size of insert (kb) 
Size of vector (kb) 
Molar ratio of insert/vector)=insert (ng)  
NdeI restriction site CATATG 
BamHI restriction site GGATCC 
Stop codon TGA 
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diameter and an attempt was made to get as many cells 
as possible. Then, each colony was transferred to a 0.5 
ml micro-tube containing 50 μl of sterile water. Vortex 
was done to disperse the cells. Then, the micro-tube 
was placed in boiling water or a heat block at 99°C for 
5 min to lyse the cells and denature DNases. Next, it 
was centrifuged at 12000×g for 1 min to remove cell 
debris. After that, 10 μl of the supernatant were trans-
ferred to a fresh 0.5 ml micro-tube to do PCR and it 
was left on ice until use. Then, a master mix was pre-
pared for colony PCR by assembling the following 
components: 1 µl dNTP mix 10 mM, 1 µl upstream 
primer, 1 µl downstream primer with 5 pmol concentra-
tion, 5 µl 10buffer with MgCl2, 0.25 µl Taq DNA 
polymerase, and 31.75 µl nuclease free water. Next, 40 
μl of the master mix were added to each 10 μl sample 
and were mixed gently and the samples were put in a 
thermal cycler. The processes in the thermal cycler for 
35 cycles included: 1 min at 94°C, 1 min at 55°C, 2 min 
at 72°C, 6 min final extension at 72°C. Then, 10-25 μl 
of the product of colony PCR were loaded per lane on a 
1% agarose gel. A strong band was appeared that had a 
size corresponding to the total number of bases of the 
region between the two primers.  
 
pET-24a transformation into E. coli BL21(DE3) expression 
system and expression of rhIGF-1 
pET-24a expression vector and E. coli BL21(DE3) 
were purchased from Pasteur Institute (Iran). Expres-
sion vector carrying the desired gene, was transformed 
into E. coli BL21 (DE3). Then, it was cultured on LB 
Agar medium and incubated for 6 hr at 37°C. Next, 
single colonies were picked up from plate, each trans-
ferred to 100 ml LB Agar containing kanamycin (30 
µg/ml final concentration) medium and incubated in 
shaker incubator at 37°C. Then, when OD600 reached 2, 
IPTG (1 mM) was added and it was incubated again for 
5-6 hr. Thus, protein expression was completed and 
IGF-1 protein was produced as inclusion bodies in bac-
terial cytoplasm. Finally, whole culture was centri-
fuged at 10000rpm. 
 
Disruption of bacterial cell and cell lysis 
After centrifugation, the sediment was weighed to 
obtain 0.2 g. Then, it was dissolved in DTT (400 ml) 
and homogenized using SOAVI homogenizer (Parma, 
Italy) (4 times with 1200 bar pressure). After the break-
down, the solution was centrifuged at 11000 rpm for  
5 min. The precipitate was weighed to obtain 0.1 g. 
Then, the precipitate was dissolved in washing buffer 
(Triton (100) 0.5%   , Tris (50 mM), EDTA (5 mM), 
and DTT (1 mM)) and incubated for 40 min at room 
temperature. Then, this solution was centrifuged at 
15000 rpm for 15 min and precipitate was dissolved in 
100 µl WFI (water for injection). 
 
Analysis of recombinant protein expression 
Gene expression was evaluated in the induced strain 
by SDS-PAGE and western blotting techniques. SDS-
PAGE was done using 20% poly-acrylamide gel and 
samples were stained by bromophenol blue. Finally, 
western blotting was done using primary polyclonal 
antibody against IGF-1 (Abcam Corporation, USA) 
and IgG secondary antibody was conjugated to HRP 
(Abcam Corporation, USA). Western blotting analysis 
was performed using anti-IGF-1 polyclonal antibody as 
the primary antibody, goat anti-rabbit antibody (IgG-
HRP) as the secondary antibody and DAB, 50X. Pro-
tein bands on SDS-PAGE were transferred to nitrocel-
lulose membrane in order to identify the production of 
hrIGF-1 in E. coli BL21 (DE3). The first incubation of 
membrane was accomplished with bovine serum albu-
min (BSA) 3% (w/v) in tris-buffered saline and PBS 
solutions for 90 min to block unspecific bands on the 
membrane. The second incubation was done by anti-
IGF-1 polyclonal antibody added at a dilution of 1:500 
in PBS solution. Anti-IgG at a dilution of 1:1000 in 
PBS solution was used in third incubation. Subsequent-
ly, incubation was performed with diaminobenzidine 
solution (DAB) for 20 min (0.5 mg/ml DAB, 0.1% H2O2). 
 
Results 
 
Cloning of IGF-1 
In order to confirm plasmid (pUC18) replication in 
E. coli DH5α, electrophoresis on 1% agarose gel was 
done following the extraction process. The sizes of 
pUC18 and IGF-1 gene were 2686 and 219 bp, respec-
tively. NdeI site and BamHI restriction sites were lo-
cated on nucleotide 183 and 429, respectively. Size of 
pUC18 digested with NdeI and BamHI restriction en-
zymes was 2440 bp. Therefore, size of pUC18-IGF-1 
was 2659 bp. The results (presence of 2659 bp band) 
indicated that pUC18 plasmids were replicated suc-
cessfully. 
 
Enzymatic digestion of pUC18 cloning vector and pET-24a 
expression vector 
After digestion of the pUC18 plasmid with two re-
striction enzymes (BamHI-HF and NdeI), electropho-
Figure 1. Electrophoresis of the products of pUC18 plasmid. Lane 1 
contained DNA ladder (Genscrip (USA)), lane 2 contained 2 bands 
representing pUC18 and IGF-1. 
10
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resis was done on 1% agarose gel and a 225 bp band 
was detected which indicated that IGF-1 gene was sub-
cloned into pUC18 plasmid successfully (Figure 1).  
 
Colony PCR 
In order to confirm ligation of the gene into expres-
sion plasmid (pET-24a), colony PCR was run. As it is 
shown (Figure 2), lane 2 contained IGF-1 sequence and 
the region was located between two primers (425 bp 
band).  
 
SDS-PAGE 
After confirmation of IGF-1 ligation into pET-24a, 
analysis of protein expression was done using SDS-
PAGE technique. As it is shown (Figure 3), there was a 
7.6 kDa band which indicated the expression of rhIGF-
1 gene.  
 
Western blotting 
Western blotting results also indicated the expres-
sion of rhIGF-1 by representing a 7.6 kDa band on ni-
trocellulose membrane (Figure 4). 
 
Discussion 
In this study, E. coli BL21 (DE3) was used as a 
cloning host to express human insulin-like growth fac-
tor type 1. Human insulin-like growth factor type 1 is 
an effective therapeutic protein for treatment of pa-
tients suffering from short stature, diabetes type 1 and 
2 as well as wound healing 
5
. So far, it has not been 
produced in Iran. So, the current study has made the 
first step for the localization of the technology of re-
combinant IGF-1 production in Iran. However, cloning 
and expression of IGF-1 only in E. coli were investi-
gated. A variety of hosts are used for production of 
therapeutic proteins such as yeast 
13,14
 and mammalian 
cells 
6
. However, due to low expression levels and 
post-translational modifications of these hosts, E. coli 
is a more suitable expression host for many cases. 
Since IGF-1 is a non-glycosylated protein, E. coli can 
be a suitable host for large-scale production of it. In 
addition, E. coli is capable to produce high amounts of 
the recombinant protein. In other studies, different 
types of E. coli have been used, but E. coli BL21(DE3) 
was used for this study because this strain has been 
engineered for high level expression of protein for rea-
sons stated above 
15
. The prokaryotic expression sys-
tems of IGF-1 such as E. coli W3110 
7
, E. coli 294 
2
, 
and E. coli HB101/PLSD1 
16
 have been used but E. coli 
BL21 (DE3) derivation of  B834 was selected in this 
paper because it contains T7 gene endogenously in its 
bacterial chromosome and produces T7 RNA polymer-
ase which in turn can increase the production of recom-
binant protein. Moreover, this strain possesses a defi-
ciency in the lon protease and lacks ompT outer mem-
brane protease. This deficiency prevents the recombi-
nant protein from damage. Our priority to choose the 
host for protein expression was the high level of the 
production of the recombinant protein. The E. coli cy-
toplasm is regarded as the first choice in protein pro-
duction owing to its high efficiency 
7,17
. However, in-
clusion body formation occurs as the result of protein 
over-expression in cytoplasm 
18
. Inclusion bodies can 
be an advantage for purification since 1) they are easily 
Figure 2. Colony PCR of IGF-1 sequence integrated into pET-24a. 
Lane 1 contained DNA Ladder (Sinagene (Iran)) and lane 2 con-
tained IGF-1 sequence or the region located between two primers 
(425 bp band). 
 
Figure 3. SDS-PAGE for analysis of the expression of IGF-1 pro-
tein in E. coli BL21 (DE3). Lane 1(protein ladder) contained protein 
ladder (Sinagene, Iran), lanes 3 and 4 contained a 7.6 kDa band, 
representing the expression of rhIGF-1 protein induced by IPTG, 
and lane 2 representing the pattern of transformed BL21 under-un-
induction condition (without IPTG). 
 
Figure 4. Analysis of the expression of rhIGF-1 using western blot-
ting technique. Lane 1 contained protein marker (Sinagene, Iran), 
lane 2 contained rhIGF-1 protein and lane 3 representing the pattern 
of transformed BL21 under un-induction (without IPTG). 
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isolated by centrifugation to yield highly concentrated 
and relatively pure protein, and 2) inclusion body for-
mation protects the protein from proteolytic attack. 
Moreover, toxic proteins may not inhibit cell growth 
when present in inactive form as inclusion bodies 
19
. 
Human IGF-1 has been expressed as inclusion bodies 
in E. coli cytoplasm.  
In this report, IGF-1 production in E. coli BL21 
(DE3) under control of T7 promoter was investigated. 
To over-produce IGF-1, pET-24a plasmid containing 
the powerful T7 promoter was used. Given the im-
portance of rhIGF-1, efforts were made to clone and 
express it in E. coli BL21(DE3). Also, identification of 
the produced recombinant protein was specifically con-
firmed by SDS-PAGE and western blotting.  
 
Conclusion 
 
In this study, the expression cassette for expression 
of human insulin growth factor type1 in Escherichia 
coli was designed and the protein was identified suc-
cessfully. E. coli BL21(DE3) can be used as a suitable 
host for the production of recombinant human insulin-
like growth factor type 1 and this technology has the 
potential to be localized in Iran.             
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